Endocytosis-dependent and spleen-selective mRNA expression enabled by ionizable lipidoid linkers enhances therapeutic mRNA vaccination
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Personalized neoantigen mRNA vaccine mitigates melanoma recurrence10.1038/s41571-024-00867-1 ↗
2. Polyplex designs for improving the stability and safety of RNA therapeutics
3. Unlocking the promise of mRNA therapeutics10.1038/s41587-022-01491-z ↗
4. The clinical progress of mRNA vaccines and immunotherapies10.1038/s41587-022-01294-2 ↗
5. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques
6. Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria10.1038/s41467-024-47460-9 ↗
7. Personalized neoantigen therapy for melanoma immunotherapy10.1038/s43018-024-00850-w ↗
8. LNP) enables mRNA delivery for cancer therapy
9. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs10.1038/s41551-021-00786-x ↗
10. Esterase-labile quaternium lipidoid enabling improved mRNA-LNP stability and spleen-selective mRNA transfection
11. Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia
12. Tuning lipid nanoparticles for RNA delivery to extrahepatic organs10.1002/adma.202401445 ↗
13. Strategies for non-viral vectors targeting organs beyond the liver
14. Why nanoparticles prefer liver macrophage cell uptake in vivo
15. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics10.1038/s12276-023-01086-x ↗
16. A diverse fibroblastic stromal cell landscape in the spleen directs tissue homeostasis and immunity10.1126/sciimmunol.abj0641 ↗
17. Splenic stromal niches in homeostasis and immunity10.1038/s41577-023-00857-x ↗
18. Structure and function of the immune system in the spleen10.1126/sciimmunol.aau6085 ↗
19. The role of lipid components in lipid nanoparticles for vaccines and gene therapy
20. Unsaturated, trialkyl ionizable lipids are versatile LNP components for therapeutic and vaccine applications
21. Combinatorial synthesis and evaluation of trialkyl galloyl amidoamine ionizable lipids for mRNA formulation10.1021/jacs.5c09030 ↗
22. Mannich reaction-based combinatorial libraries identify antioxidant ionizable lipids for mRNA delivery with reduced immunogenicity
23. Carbonate-bearing ionizable lipids for mRNA delivery to splenic NK cells10.1021/jacs.5c01389 ↗
24. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d
25. Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution10.1038/s41551-024-01267-7 ↗
26. Multicomponent synthesis of imidazole-based ionizable lipids for highly efficient and spleen-selective messenger RNA delivery10.1021/jacs.4c00451 ↗
27. Epstein–Barr virus as a potentiator of autoimmune diseases10.1038/s41584-024-01167-9 ↗
28. Latency and lytic replication in Epstein–Barr virus-associated oncogenesis10.1038/s41579-019-0249-7 ↗
29. Epstein-Barr virus: biology and clinical disease10.1016/j.cell.2022.08.026 ↗
30. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990–201010.1186/1750-9378-9-38 ↗
31. EBV based cancer prevention and therapy in nasopharyngeal carcinoma10.1038/s41698-017-0018-x ↗
32. Epstein-Barr virus-encoded microRNAs as regulators in host immune responses10.7150/ijbs.24562 ↗
33. Epstein-Barr Virus: an important vaccine target for cancer prevention10.1126/scitranslmed.3002878 ↗
34. Unlocking the therapeutic applicability of LNP-mRNA: chemistry, formulation, and clinical strategies10.34133/research.0370 ↗
35. Drug delivery systems for RNA therapeutics10.1038/s41576-021-00439-4 ↗
36. Self-assembled mRNA vaccines10.1016/j.addr.2020.12.014 ↗
37. Iterative design of ionizable lipids for intramuscular mRNA delivery10.1021/jacs.2c10670 ↗
38. Nucleic acid delivery by lipid nanoparticles for organ targeting10.1016/j.cclet.2025.110849 ↗
39. Lipid nanoparticles optimized for targeting and release of nucleic acid
40. Acid-degradable lipid nanoparticles enhance the delivery of mRNA10.1038/s41565-024-01765-4 ↗
41. Replacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation10.1126/sciadv.ady6460 ↗
42. Epstein–Barr virus and cancer10.1146/annurev-pathmechdis-012418-013023 ↗
43. Research landmarks on the 60th anniversary of Epstein-Barr virus10.1007/s11427-024-2766-0 ↗
44. Advantages and limitations in the establishment and utilization of patient-derived xenografts in gastric cancer10.1007/s10330-016-0187-7 ↗
45. Advances in basic and translational research into nasopharyngeal carcinoma10.1097/ot9.0000000000000071 ↗